Summary
In a double-blind, randomized, placebo-controlled study comparing verapamil and placebo in late secondary intervention after acute myocardial infarction, the physicians were asked to try to identify the treatment in 100 consecutive patients. The assessment of the presumed treatment was based upon the presence of effects and side effects. It was only possible correctly to group 36% (95%: 26.7-46.2) of the patients. 35 patients were grouped as indeterminable. In 65 a treatment was proposed, correctly in 55%, and thus ideal blindedness had been achieved.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Svedmyr N (1979) The placebo effect. Scand J Rehab Med 11: 169–172
The Danish Study Group on Verapamil in Myocardial infarction (1984) Verapamil in acute myocardial infarction. Eur Heart J 5: 516–528
The Danish Study Group on Verapamil in Myocardial infarction (1984) Abrupt withdrawal of verapamil in ischaemic heart dis- ease. Eur Heart J 5: 529–532
Byington RP, Curb JD, Mattson ME (1985) Assessment of double-blindness at the conclusion of the beta-blocker heart at- tack trial. JAMA 253:1733–1736
Author information
Authors and Affiliations
Consortia
Additional information
The purpose of the present study was to examine the degree of blinding in a placebo-controlled, double-blind trial of late secondary intervention after acute myocardial infarction.
Rights and permissions
About this article
Cite this article
Jespersen, C.M., the Danish Study Group on Verapamil in Myocardial Infarction. Short Communications Assessment of blindness in the danish verapamil infarction trial II (DAVIT II) . Eur J Clin Pharmacol 39, 75–76 (1990). https://doi.org/10.1007/BF02657062
Received:
Revised:
Issue Date:
DOI: https://doi.org/10.1007/BF02657062